Evidence map›Paper›PMID 39976718›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Exploring the therapeutic potential of natural products in modulating miRNA networks in prostate cancer.

Osama A Mohammed

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Osama A MohammedDepartment of Pharmacology, College of Medicine, University of Bisha, 61922, Bisha, Saudi Arabia. oamohamed@ub.edu.sa.ORCID 0000-0001-9712-9609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PC) is the most common cancer among men and the second leading cause of cancer-related deaths in the USA. It remains a significant health challenge, necessitating the exploration of novel therapeutic strategies. It primarily manifests as adenocarcinoma, which arises from glandular cells in the prostate gland, located below the bladder. While many men may not experience symptoms in the early stages, as the disease progresses, symptoms can include difficulty urinating, erectile dysfunction, and pelvic or back pain. MicroRNAs (miRNAs) are small, non-coding RNA molecules, typically consisting of 21 to 23 nucleotides, that play a vital role in regulating gene expression. miRNAs are found across a variety of organisms, including plants, animals, and some viruses. Their primary function is to modulate the expression of target genes, thereby influencing numerous biological processes such as development, differentiation, proliferation, and apoptosis. Natural compounds such as curcumin, ellagitannin, diindolylmethane, epigallocatechin-3-gallate (EGCG), resveratrol, genistein, luteolin, capsaicin, and berberine have been shown to modulate miRNA expression in PC, contributing to their anticancer effects. These compounds influence the expression of both tumor-suppressor and oncogenic miRNAs, thereby impacting critical pathways related to cell proliferation, apoptosis, and metastasis. Recent studies indicate that the deregulation of miRNA networks plays a critical role in cancer progression, and natural compounds have emerged as potential modulators of these pathways. Through a comprehensive literature survey, we identified various phytochemicals that exhibit anticancer properties by influencing miRNA expression. These natural agents can alter miRNA levels through direct binding, epigenetic modifications, or interaction with proteins involved in miRNA biogenesis. The findings underscore the potential of integrating natural agents into therapeutic approaches for PC, paving the way for innovative miRNA-targeted treatments. This review not only elucidates the molecular mechanisms underlying the health benefits of natural compounds but also highlights their promise in developing effective cancer therapies.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicBiological ProductsMicroRNAsProstatic NeoplasmsAnimalsGene Expression Regulation, NeoplasticHumansMaleAntineoplastic AgentsAntineoplastic Agents, PhytogenicBiological ProductsMicroRNAsDiagnosisNatural productsOncogenic miRNAsPathogenesisProstate cancerTumor suppressor miRNAs

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.